Sabby Management’s TG Therapeutics TGTX Stock Holding History

Sabby Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-490	Closed	-$492K	–	204
2017 Q2	$492K	Hold	490	–	–	0.03%	139
2017 Q1	$571K	Buy	+490	New	+$3.52K	0.03%	167

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Sabby Management's TGTX Position: Q1 2014 in Review

Sabby Management sold out of TG Therapeutics (TGTX) in Q1 2014, closing a stake of 66,000 shares — an estimated $257K sold.

Sabby Management first reported a position in TGTX in Q3 2013 and held it in 2 quarters. The position peaked at $1.4M in Q3 2013. 51 funds tracked by Wall St. Rank hold TGTX as of Q1 2014.

Sabby Management reported no remaining TG Therapeutics position as of Q1 2014 after selling out during the quarter.
Sabby Management sold 66,000 TG Therapeutics shares in Q1 2014, an estimated $257K.
Sabby Management first reported a position in TG Therapeutics in Q3 2013 and held it in 2 quarters.
Sabby Management's TG Therapeutics position peaked at $1.4M in Q3 2013.
51 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2014.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.